2026-06-07T23:44:11Zhttps://docta.ucm.es/rest/oai/requestoai:docta.ucm.es:20.500.14352/74322023-08-27T11:22:45Zcom_20.500.14352_14col_20.500.14352_15
Docta Complutense
author
Romero Martínez, Manuel Alejandro
author
Ramos Alonso, Eva
author
López Muñoz, Francisco
author
Ríos, Cristóbal de los
author
Egea, Javier
author
Gil Martín, Emilio
author
Pita Pita, Rene
author
Torrado Durán, Juan José
author
Serrano López, Dolores Remedios
author
Juberias, Antonio
2023-06-17T08:33:23Z
2023-06-17T08:33:23Z
2021-04-10
2079-9721
10.3390/diseases9020027
https://hdl.handle.net/20.500.14352/7432
https://www.mdpi.com/journal/diseases
Blister or vesicant chemical warfare agents (CWAs) have been widely used in different military conflicts, including World War I and the Iran-Iraq War. However, their mechanism of action is not fully understood. Sulfur and nitrogen mustard exert toxic effects not only through the alkylation of thiol-bearing macromolecules, such as DNA and proteins, but also produce free radicals that can develop direct toxic effects in target organs such as the eyes, skin, and respiratory system. The lack of effective treatments against vesicant CWAs-induced injury makes us consider, in this complex scenario, the use and development of melatonin-based therapeutic strategies. This multifunctional indoleamine could facilitate neutralization of the oxidative stress, modulate the inflammatory response, and prevent the DNA damage, as well as the long-term health consequences mediated by vesicant CWAs-induced epigenetic mechanisms. In this context, it would be essential to develop new galenic formulations for the use of orally and/or topically applied melatonin for the prophylaxis against vesicant CWAs, as well as the development of post-exposure treatments in the near future.
eng
Atribución 3.0 España
Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?
journal article
URL
https://docta.ucm.es/bitstreams/f4ab9c36-6459-4caa-9287-dc562c3e9213/download
File
MD5
a34d43dd7360dc3b124c09fd4c97c9d5
2509293
application/pdf
diseases-09-00027.pdf